Oral contraceptives and venous thromboembolism (Q41140574)

27 September 2017

1 reference

title

Oral contraceptives and venous thromboembolism (English)

1 reference

27 September 2017

main subject

venous thromboembolism

1 reference

L Speroff

1

1 reference

27 September 2017

publication date

1 July 1996

1 reference

International Journal of Gynecology and Obstetrics

27 September 2017

published in

1 reference

27 September 2017

volume

54

1 reference

27 September 2017

issue

1

1 reference

27 September 2017

page(s)

45-50

1 reference

Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2F0020-7292%2896%2902669-0

Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0020-7292%2896%2902669-0

Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0020-7292%2896%2902669-0

Protein binding of active ingredients and comparison of serum ethinyl estradiol, sex hormone-binding globulin, corticosteroid-binding globulin, and cortisol levels in women using a combination of gestodene/ethinyl estradiol (Femovan) or a combinatio

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0020-7292%2896%2902669-0

Third generation oral contraception and venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0020-7292%2896%2902669-0

Resistance to activated protein C as a basis for venous thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0020-7292%2896%2902669-0

World distribution of factor V Leiden

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0020-7292%2896%2902669-0

Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0020-7292%2896%2902669-0

Interaction with the pharmacokinetics of ethinylestradiol and progestogens contained in oral contraceptives

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0020-7292%2896%2902669-0

Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0020-7292%2896%2902669-0

Safety of combined oral contraceptive pills

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0020-7292%2896%2902669-0

Factor V Leiden--an unselfish gene?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0020-7292%2896%2902669-0

Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0020-7292%2896%2902669-0

10.1016/0020-7292(96)02669-0

21 January 2018

Identifiers

DOI

1 reference

27 September 2017

1 reference